Correlation of cell apoptosis index and hematology profile in children with acute myeloblastic leukemia with chemotherapy induction
Main Article Content
Keywords
Acute Myeloblastic Leukemia, Cell Apoptosis Index, Chemotherapy, Hemoglobin, Absolute Neutrophile Count
Abstract
Background: Acute myeloblastic leukemia (AML) is one of the most prevalent pediatric neoplasms, with a poor prognosis and high risk of relapse. Response to induction of chemotherapy and complication occurrence are crucial in the AML patient's outcome. Chemotherapy can induce apoptosis in a cancer cell and the blood cell as a side effect that can cause severe complications. This study aims to evaluate the cell apoptosis index and its correlation with hematologic profile (hemoglobin, leucocyte, thrombocyte, absolute neutrophile count/ANC) between induction chemotherapy administration.
Methods: Observational study was performed on children with AML who will undergo induction chemotherapy. The cell apoptosis index and the hematologic profile were evaluated before and after induction chemotherapy. The data was then analyzed to compare the cell apoptosis index and its correlation with the hematologic profile.
Result: The mean age of the subjects was 13.6 years old, similar to previous epidemiologic studies, which showed the main incidence at 15 years old. There was a significant increase in cell apoptosis index (p=0.014) and a significant decrease in hemoglobin level (p=0.031) and ANC (p=0.05). The cell apoptosis index had a significantly strong negative correlation with all hematologic profiles.
Conclusion: Cell apoptosis index increased after induction chemotherapy in pediatric AML and correlated with the hematologic profile.
References
2. Stevens M, Frobisher C, Hawkins M, Jenney M, Lancashire E, Reulen R, et al. The British Childhood Cancer Survivor Study: Objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer. 2008;50(5):1018–25.
3. Permono HB, Sutaryo, Ugrasena I, Windiastuti E, Abdulsalam M. Buku Ajar Hematologi-Onkologi Anak. Buku ajar Hematol anak. 2006;236–47.
4. Villela L, Bolaños-Meade J. Acute myeloid leukaemia: optimal management and recent developments. Drugs. 2011;71(12):1537–50. Available from: https://pubmed.ncbi.nlm.nih.gov/21861539
5. Kaspers GJL, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19(12):2025–9. Available from: http://dx.doi.org/10.1038/sj.leu.2403958
6. Schmiegelow K, Nesting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J, et al. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood & Cancer. 2016;63(12):2104–11. Available from: http://dx.doi.org/10.1002/pbc.26139
7. Perdani RRW, Sudarmanto B. Hematological parameters and remission induction of childhood acute lymphoblastic leukemia. Paediatr Indones. 2018;58(2):71–4. Available from: http://dx.doi.org/10.14238/pi58.2.2018.71-4
8. F C, TS S. Clinical and Hematological Profile of Acute Myeloid Leukemia (AML) Patients of Sindh. J Hematol & Thromboembolic Dis. 2016;04(02). Available from: http://dx.doi.org/10.4172/2329-8790.1000239
9. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–41. Available from: http://dx.doi.org/10.1038/nrm2312
10. Singh A, Bhatia P, Trehan A, Bansal D, Singh A, Bhatia A. Low spontaneous apoptosis index at diagnosis predicts a high-risk phenotype in paediatric acute lymphoblastic leukaemia. Indian J Med Res. 2018;147(3):248–55. Available from: https://pubmed.ncbi.nlm.nih.gov/29923513
11. Malinowska I, Wasik M, Stelmaszczyk A, Górska E, Steczowicz M, Rokicka-Milewska R. Evaluation of Spontaneous and Therapeutically Induced Apoptosis in Childhood Leukemias [Internet]. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion. Springer Berlin Heidelberg; 2001. p. 124–7. Available from: http://dx.doi.org/10.1007/978-3-642-18156-6_22
12. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–205. Available from: http://dx.doi.org/10.1182/blood-2012-03-362608
13. Williams LA, Richardson M, Marcotte EL, Poynter JN, Spector LG. Sex ratio among childhood cancers by single year of age. Pediatr Blood Cancer. 2019/02/28. 2019;66(6):e27620–e27620. Available from: https://pubmed.ncbi.nlm.nih.gov/30815990
14. Murphy T, Yee KWL. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2017;18(16):1765–80. Available from: http://dx.doi.org/10.1080/14656566.2017.1391216
15. Carlesso N, Cardoso AA. Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Curr Opin Hematol. 2010;17(4):281–6. Available from: http://dx.doi.org/10.1097/moh.0b013e32833a25d8
16. Kurtin MS, AOCN®, ANP-C, Sandra E. RN. Myeloid Toxicity of Cancer Treatment. J Adv Pract Oncol. 2012;3(4). Available from: http://dx.doi.org/10.6004/jadpro.2012.3.4.2